The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Aug. 18, 6:33 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #12. OPKO Health, Inc. Inspiro Medical Ltd.

Acquirer: OPKO Health, Inc. (NASDAQ:OPK)
Acquiree: Inspiro Medical Ltd.
Details: OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Inspiro Medical Ltd. ("Inspiro"), an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices.

Opko Health is a healthcare company. Co.'s segments are: diagnostics, which consists of the clinical laboratory operations of its subsidiary BioReference Laboratories, Inc. (BioReference), as well as its point-of-care operations; and pharmaceutical, which consists of the pharmaceutical operations Co. operates in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, Co. provides laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare.

OPK SEC Filing Email Alerts Service


Open the OPK Page at The Online Investor »

Company Name: 
OPKO Health Inc
Website: 
www.opko.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding OPK: 
33
Total Market Value Held by ETFs: 
$153.28M
Total Market Capitalization: 
$2.02B
% of Market Cap. Held by ETFs: 
7.61%
 

Open the OPK Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree OPK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.50 out of 4)
49th percentile
(ranked lower than approx. 51% of all stocks covered)

Analysts' Target Price:
OPK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 12 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.